抗プロゲスティン療法では,乳がんリスクの特徴を標的とする
Bruno M Simões1, Robert Pedley2,3,4, Curtis W McCloskey5,6,7
1Manchester Breast Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. bruno.simoes@manchester.ac.uk.
Nature
|November 5, 2025
まとめ
ウリプリスタルアセテートによる抗プロゲスティン治療は,閉経前の女性における乳がんリスクマーカーを低下させた. このプロゲステロン受容体の抗体療法により,重要な細胞の増殖が抑制され,組織の微小環境が変化しました.
科学分野:
- 腫瘍学
- 分子生物学
- 生物医学工学
背景:
- 乳がんは特に女性にとって 世界的に深刻な健康問題です
- 効果的な予防戦略を策定することは,死亡率を減らすために極めて重要です.
- 閉経前の乳腺組織は リスク軽減のユニークなターゲットです
研究 の 目的:
- 乳がんリスクマーカーの減少におけるプロゲステロン受容体アンタゴニストであるウリプリスタルアセテートの有効性を評価する.
- 抗プロゲスティン療法によって誘発された分子および組織レベルの変化を調査する.
- 乳がんの発生と予防における腫瘍の微小環境の役割を調査する.
主な方法:
- 乳がん予防研究1 (BC-APPS1) は24人の閉経前女性を対象とした.
- 多層のOMIC (ゲノミクス,プロテオミクス) と生細胞アッセイを使用した.
- 臨床画像 (MRI) と組織微力学 (原子力顕微鏡) が統合されました.
主要な成果:
- ウリプリスタルアセテートは,上皮細胞増殖 (Ki67) と光細胞を著しく減少させた.
- 治療により,線維腺の体積が減り,細胞外マトリックスが再構築された.
- コラーゲン組織の減少と組織の硬さが観察され,コラーゲンVIのダウンレギュレーションはプロジェニータ細胞活動と関連していた.
結論:
- ウリプリスタルアセテートによるプロゲステロン受容体の対抗は,閉経前の乳がんの予防の可能性を示しています.
- この治療は前身細胞を抑制し ストロマの微小環境を改造することで作用します
- この研究は,分子および組織メカニズムを標的とした早期がん予防試験の枠組みを提供します.
関連する概念動画
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Disorders of the Female Reproductive System
3.8K
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
3.8K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
450
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
450
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K


